Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4512 in relapsed/refractory B-cell non-Hodgkin lymphoma (Lumi-NHL)
NCT07123454Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Primary completion
- Jul 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 8
01
Overview
Phase 2, open-label trial of AZD4512 in B-cell non-Hodgkin lymphoma (2 arms), sponsored by AstraZeneca. Primary endpoints: Dose-Limiting Toxicities at 4 weeks, Treatment-Emergent, Treatment-Related, and Serious Adverse Events and 2 more. Started Sep 2025; status: recruiting.
02
Drugs
AZD4512
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07123454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07123454.